hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06302595 id: 2022P001093 id: 5R44CA224853 type: NIH link: https://reporter.nih.gov/quickSearch/5R44CA224853 briefTitle: MRI Guided Prostate Biopsy overallStatus: RECRUITING date: 2023-08-24 date: 2024-05-31 date: 2024-08-31 date: 2024-03-12 date: 2024-03-12 name: Brigham and Women's Hospital class: OTHER name: National Cancer Institute (NCI) name: Physical Sciences Inc. briefSummary: This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibility in this study is defined as whether the needle holder frame enables accurate tissue sampling from a suspicious region in the prostate found on an MR image. If it does, a biopsy can be carried out with the needle holder frame safely in a clinical routine. The study will be conducted during a routine MR-guided prostate biopsy procedure with an investigational needle holder frame instead of a conventional needle-guiding template. conditions: Suspected Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 15 type: ESTIMATED name: MRI-guided prostate biopsy using the needle holder frame. measure: Accuracy of needle placement sex: MALE minimumAge: 30 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital status: RECRUITING city: Boston state: Massachusetts zip: 02115 country: United States name: Kemal Tuncali, MD role: CONTACT phone: 617-732-7631 email: ktuncali@bwh.harvard.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06302582 id: stress injury briefTitle: Platelet Rich Plasma Combined With Human Umbilical Cord Mesenchymal Stem Cells for Stage 3 and 4 Stress Injury overallStatus: RECRUITING date: 2024-02-29 date: 2024-11-25 date: 2024-11-25 date: 2024-03-12 date: 2024-03-12 name: Liaocheng People's Hospital class: OTHER briefSummary: This study is an open-label, single-center trial which aim to evaluate of efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) combined with platelet-rich plasma (PRP) in stage 3 and 4 stress injury. conditions: Pressure Injuries - Stage 3 conditions: Pressure Injuries - Stage 4 studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs) name: Control group measure: Change From Baseline in Pressure Ulcer Scale for Healing (PUSH) measure: Change from baseline in Determination of growth factor content measure: Wound healing time measure: Positive rate of bacterial culture measure: Safety evaluation sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Central laboratory status: RECRUITING city: Liaocheng state: Shandong zip: 252000 country: China name: changhui Zhou, postgraduate role: CONTACT phone: 13562078772 email: zhouchanghui008@163.com lat: 36.45596 lon: 115.97766 hasResults: False
nctId: NCT06302569 id: Bellini INT 2024-511587-93-00 briefTitle: Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma acronym: REPRINT overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-10 date: 2028-05 date: 2024-03-08 date: 2024-03-08 name: Giuseppe Procopio class: OTHER briefSummary: This is a single-arm, monocentric, phase II trial, enrolling patients with histological diagnosis of collecting duct carcinoma and renal medullary carcinoma with locally advanced or metastatic disease who will be treated with Pembrolizumab plus Enfortumab Vedotin.
Approximately, 23 patients will be enrolled. At screening, pre-existing archival primary and metastatic FFPE tumor specimen will be collected and submitted for central pathology review and translational analysis. All participants will undergo baseline screening imaging for clinical staging. Patients will be treated with Pembrolizumab q21 plus Enfortumab Vedotin 1,8q21 for 3 cycles (3 infusion of Pembrolizumab and 6 infusion of Enfortumab Vedotin) then radiological imaging will be repeated and patients with SD, PR or CR will continue pembrolizumab until disease progression, unacceptable toxicities or completion of treatment (17 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice.
The study will also involve collection of a blood sample taken at the commencement of treatment, at the first cycle, after cycle 3 and at the end of treatment or progression of disease, to be used for research purposes. conditions: Bellini Carcinoma conditions: Collecting Duct Carcinoma conditions: Renal Medullary Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 23 type: ESTIMATED name: Pembrolizumab + Enfortumab Vedotin measure: ORR in patients treated with Pembrolizumab plus Enfortumab Vedotin measure: Progression-free survival (PFS) in patients treated with Pembrolizumab plus Enfortumab Vedotin measure: Overall-survival (OS) in patients treated with Pembrolizumab plus Enfortumab Vedotin measure: Number of Participants treated with Pembrolizumab + Enfortumab Vedotin who experience AEs/SAEs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Irccs Istituto Dei Tumori Di Milano city: Milan zip: 20133 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06302556 id: 2022XJ9W4F id: G53D2300526 0006 type: OTHER_GRANT domain: Ministry of University and Research. NextGenetationUE briefTitle: The Role of Immune Checkpoints in Lung Transplant (ILTRA) acronym: ILTRA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-01 date: 2026-02 date: 2024-03-08 date: 2024-03-08 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER name: University of Milan name: University of Padova name: University of Turin, Italy briefSummary: The goal of this observational study is to learn about rejection in lung transplantation.
• what is the role of immune checkpoints in lung transplantation? Participants will describe pathways of rejection in lung transplantation analyzing the immune checkpoints on explanted lungs as well as trans-bronchial biopsies. conditions: Lung Transplant Rejection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 280 type: ESTIMATED name: Immune checkpoints analysis name: Gene expression analysis measure: Lung-tissue immune-checkpoint profile and bronchoalveolar immune-cells mRNA signature in acute rejection after lung transplantation. measure: Lung-tissue immune-checkpoint profile in chronic rejection after lung transplantation. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico city: Milan zip: 20122 country: Italy name: Mario Nosotti, Medicine role: CONTACT phone: 3393924679 email: mario.nosotti@unimi.it name: Ilaria Righi, Medicine role: CONTACT phone: +393470556707 email: ilaria.righi78@gmail.com name: Mario Nosotti, Medicine role: PRINCIPAL_INVESTIGATOR name: Ilaria Righi, Medicine role: SUB_INVESTIGATOR name: Lorenzo Rosso, Medicine role: SUB_INVESTIGATOR name: Valentina Vaira, Biology role: SUB_INVESTIGATOR name: Mario Clerici, Medicine role: SUB_INVESTIGATOR name: Daria Trabattoni, Biology role: SUB_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: University of Modena and Reggio Emilia city: Modena zip: 41121 country: Italy name: Marcello Pinti, Biology role: CONTACT phone: +390592055386 email: marcello.pinti@unimore.it lat: 44.64783 lon: 10.92539 facility: University of Padua city: Padova zip: 35131 country: Italy name: Marco Schiavon, Medicine role: CONTACT phone: +39 3475642901 email: marco.schiavon@unipd.it lat: 45.40797 lon: 11.88586 facility: University of Turin city: Torino zip: 10124 country: Italy name: Massimo Boffini, Medicine role: CONTACT phone: +39 3474267034 email: massimo.boffini@unito.it lat: 45.07049 lon: 7.68682 hasResults: False
nctId: NCT06302543 id: POI bone marrow briefTitle: Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells acronym: alfarah overallStatus: RECRUITING date: 2024-03-01 date: 2024-09-10 date: 2024-10-24 date: 2024-03-08 date: 2024-03-08 name: abdulmajeed hammadi class: INDUSTRY briefSummary: investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-Mullerian hormone.
Autologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program. conditions: Premature Ovarian Insufficiency studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: single armed interventional study primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: autologous bone marrow cells injection measure: change in gonadotropin levels sex: FEMALE minimumAge: 30 Years maximumAge: 60 Years stdAges: ADULT facility: Ministry of Health status: RECRUITING city: Baghdad zip: 964 country: Iraq name: abdulmajeed Hammadi, MD role: CONTACT phone: +9647902268105 email: alzaitounhospital@gmail.com lat: 33.34058 lon: 44.40088 hasResults: False
nctId: NCT06302530 id: UCV/2022-2023/155 briefTitle: "Effectiveness of the Ultrasound - Guided Lengthening of the Gastrocsoleus Complex" acronym: EUGLGC overallStatus: RECRUITING date: 2024-03-15 date: 2024-08-30 date: 2025-03-15 date: 2024-03-08 date: 2024-04-23 name: Fundación Universidad Católica de Valencia San Vicente Mártir class: OTHER briefSummary: This research project compares the effectiveness of different surgical techniques for lengthening the gastrocnemius-soleus system in patients with equinus deformity. The study will compare 2 techniques: gastrocnemius tendon recession (Strayer) and plantaris resection. Increased ankle range of motion, complications, operative time, recovery time, pain scales and function will be measured. The results will help determine which technique is most effective and safe for correcting equinus deformity. conditions: Gastrocnemius Equinus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: To reduce bias, the study will use double-blind blinding. Patients will not know the group to which they have been assigned. In addition, the assessors performing the ankle range of motion measurements by goniometry will be blinded to each patient's treatment group.
In this way, the aim is to reduce the possibility of knowledge of the assigned treatment influencing the evaluation of the results, both on the part of the patients and of the evaluators and analysts. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: Stayer name: Plantar transection measure: Ankle range of motion measure: Visual Analog Scale. measure: American Orthopedic Foot and Ankle Score measure: Complications sex: ALL minimumAge: 10 Years maximumAge: 90 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Podologia Avançada status: RECRUITING city: Granollers state: Barcelona zip: 08401 country: Spain name: Lluis Castillo-Sanchez, Dr role: CONTACT phone: 610143173 email: info@podologiaavanzadabcn.com name: Lluis Castillo, Dr role: SUB_INVESTIGATOR name: Cristina Razzano role: PRINCIPAL_INVESTIGATOR name: Simone Moroni role: SUB_INVESTIGATOR lat: 41.60797 lon: 2.28773 facility: Clinica Mayral foot center status: RECRUITING city: Barcelona state: Barcelon zip: 08029 country: Spain name: Jordi Mayral role: CONTACT phone: (+34) 93 339 78 41 email: barcelona@clinicamayral.com name: Jordi Mayral role: SUB_INVESTIGATOR name: Cristina Razzano role: PRINCIPAL_INVESTIGATOR name: Simone Moroni role: SUB_INVESTIGATOR lat: 41.38879 lon: 2.15899 facility: Clinica Pasito a pasito status: RECRUITING city: Valencia zip: 46008 country: Spain name: Javier Ferrer-Torregrosa, Dr role: CONTACT phone: 963855535 email: clinicaspasitoapasito@gmail.com name: Javier Ferrer-Torregrosa, Dr role: CONTACT phone: 644733882 email: javier.ferrer@ucv.es name: JAVIER Ferrer- TORREGROSA, Dr role: PRINCIPAL_INVESTIGATOR lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06302517 id: K2020097 briefTitle: Bis Monitoring Effect on Delirium Occurrence and Nursing Quality Improvement Recovering From General Anesthesia overallStatus: COMPLETED date: 2020-09-01 date: 2022-05-31 date: 2022-08-29 date: 2024-03-08 date: 2024-03-08 name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: ①Effects of BIS Index (BIS) monitoring on delirium incidence in Post-anesthesia care unit (PACU) in patients undergoing general anesthesia
②Effects of BIS BIS Index (BIS) monitoring on the quality of nursing care in the Post-anesthesia care unit (PACU) conditions: Delirium, Postoperative studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 134 type: ACTUAL name: BIS-guided measure: Ricker sedation-agitation scale measure: The nursing activity score (NAS) measure: vital signs （Mean arterial pressure, heart rate, pulse oxygen saturation ） measure: Comparison of complications during the PACU period measure: The comprehensive satisfaction score sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Fourth Affiliated Hospital, School of Medicine, Zhejiang University city: Jinhua state: Zhejiang zip: 322000 country: China lat: 29.10678 lon: 119.64421 hasResults: False
nctId: NCT06302504 id: Nature briefTitle: Nature-based Mindfulness Intervention Program for Family Carers overallStatus: RECRUITING date: 2023-04-15 date: 2024-03-31 date: 2024-03-31 date: 2024-03-08 date: 2024-03-08 name: The Hong Kong Polytechnic University class: OTHER briefSummary: The program integrates ordinary mindfulness exercise with nature environment. Participants will be able to practice mindfulness in a natural environment in some of the program sessions. The study will study the effects of nature-based mindfulness program in reducing caregiving stress. The program will last for 4 session, 8 hours in total. conditions: Mental Health Issue studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: Nature-based mindfulness program measure: depression measure: anxiety measure: stress measure: family functioning measure: family conflict measure: well-being sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Hong Kong Polytechnic University status: RECRUITING city: Hong Kong zip: 852 country: Hong Kong name: Hay-ming Herman Lo, PhD role: CONTACT phone: +852-27665769 email: herman.lo@polyu.edu.hk lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06302478 id: KhonKaenU001 briefTitle: 5E Program for Preventing Venous Thromboembolism in Patients With Spinal Cord Disorders overallStatus: RECRUITING date: 2024-03-12 date: 2024-05-30 date: 2024-10-31 date: 2024-03-08 date: 2024-03-13 name: Khon Kaen University class: OTHER briefSummary: The goal of this quasi-experimental study is to examine the effects of a venous thromboembolism prevention program, or "5E" program, on the rates of venous thromboembolism in patients with spinal cord disorders. The main questions it aims to answer are:
* Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission conditions: Venous Thromboembolism conditions: Spinal Cord Diseases conditions: Spinal Cord Injuries conditions: Nurse's Role studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: A quasi-experimental research (two group pretest-posttest design) primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 42 type: ESTIMATED name: 5E program measure: The rate of venous thromboembolism measure: Signs and symptoms of deep venous thrombosis and pulmonary embolism measure: Thigh and calf circumference sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chaiyaphum Hospital status: RECRUITING city: Chaiyaphum zip: 36000 country: Thailand name: Suchada Chindamart, BNS role: CONTACT phone: +66619411828 email: suchada.chi@kkumail.com lat: 15.81047 lon: 102.02881 hasResults: False
nctId: NCT06302465 id: PKUPH-sarcoma 18 briefTitle: Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells overallStatus: RECRUITING date: 2024-05-01 date: 2026-11-01 date: 2026-12-31 date: 2024-03-08 date: 2024-03-29 name: Peking University People's Hospital class: OTHER briefSummary: Malignant tumor of bone is rare with poor prognosis. Surgery is the main treatment for non- metastatic bone tumor. Although neoadjuvant chemotherapy for non-metastatic bone tumor cannot improve survival rate based on adjuvant chemotherapy, it can reduce and clarify tumor boundary. Control of local recurrence rate is the core objective of oncotherapy. Surgery way and boundary have a significant effect on prognosis of non- metastatic bone tumor. Narlumosbartmab, a RANKL inhibitor, can make tumor boundary clear and reduce surgical difficulty by inhibiting osteoclast. This is a prospective, randomized, controlled, two-arm, open, single-center clinical trial to compare the efficacy and safety of narlumosbartmab combined with neoadjuvant chemotherapy and neoadjuvant chemotherapy alone in bone-derived malignancies with bone lytic lesions and multinucleated giant cells. Investigators mainly observe the local recurrence rate to evaluate the survival benefit for patients with poor prognosis. conditions: Malignant Bone Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide name: doxorubicin、cisplatin、methotrexate、ifosfamide measure: local recurrence rate measure: tumor necrosis rate measure: R0 removal rate measure: Event-free survival measure: Overall survival sex: ALL minimumAge: 8 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University People's Hospital status: RECRUITING city: Beijing state: Beijing zip: 100044 country: China name: Lu Xie, M.D. role: CONTACT phone: +8613401044719 email: xie.lu@hotmail.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06302452 id: IRB00433605 id: R01MD019173 type: NIH link: https://reporter.nih.gov/quickSearch/R01MD019173 briefTitle: Adult Trauma Centers RE-AIM at Gun Safety (ACTFAST) Prevention overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-02 date: 2028-02 date: 2024-03-08 date: 2024-03-08 name: Johns Hopkins University class: OTHER name: National Institute on Minority Health and Health Disparities (NIMHD) name: Rhode Island Hospital briefSummary: The goal of this interventional study is to evaluate the implementation and effectiveness of a comprehensive a universal firearm injury prevention program, ACTFAST (Adopting Comprehensive Training for FireArm Safety in Trauma centers), in level 1 trauma centers. The main aims of the study are:
2. (Primary Aim 2) Assess firearm injury prevention knowledge, attitudes, and safe storage practices among trauma patients treated within participating trauma centers. conditions: Firearm Injury conditions: Safety Issues studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: The trial uses a unidirectional crossover stepped wedge design with a sequential roll-out of the intervention, ACTFAST, RE-AIM implementation framework, over several discrete time points or "steps." Each of the three trauma centers will be randomly assigned to one step that will determine when they crossover from control to implementation.
Data are collected over multiple wedges, each 4-6 months in length. During the first wedge, none of the participating trauma centers will receive ACTFAST. During the second wedge, the first trauma center completes the Adoption and Implementation period. Over the third wedge, the first center shifts to the Maintenance period, the second trauma center enters the Adoption and Implementation period, and the remaining cohort stays in the control condition. This pattern continues until all trauma centers have progressed from control condition through the active implementation period. primaryPurpose: OTHER masking: NONE count: 1776 type: ESTIMATED name: Adopting Comprehensive Training for FireArm Safety in Trauma Centers measure: Proportion of admitted injured patients receiving each element of the ACTFAST Program measure: Percentage of admitted injured patients receiving elements of the ACTFAST Program measure: Patient firearm safety attitudes and behaviors as assessed by survey measure: Clinician firearm safety knowledge and confidence as assessed by survey sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins Bayview Medical Center city: Baltimore state: Maryland zip: 21224 country: United States lat: 39.29038 lon: -76.61219 facility: Johns Hopkins Hospital city: Baltimore state: Maryland zip: 21287 country: United States lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06302439 id: INZ701-007 briefTitle: PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2034-05 date: 2034-05 date: 2024-03-08 date: 2024-03-18 name: Inozyme Pharma class: INDUSTRY name: GACI Global briefSummary: The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudinally. The registry will prospectively gather information about the genetic, biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes \[PROs\]) of each disease during routine, standard-of-care visits, with the aim of developing a comprehensive understanding of the burden of illness and progressive nature of the disease. conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency conditions: ATP-Binding Cassette Subfamily C Member 6 Deficiency studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: No Intervention for this observational study measure: Characterization of the natural history of ENPP1 Deficiency and the infantile-onset form of ABCC6 Deficiency longitudinally measure: Assessment of Patient Functional changes through a validated Patient Reported Outcomes (PROs) tool measure: Assessment of Health-Related Quality-of-Life (HRQoL) changes through validated Patient Reported Outcomes (PROs) tools measure: Measurement of inorganic phosphate (PPi) levels in patients' venous blood sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False